

Projected Patent Expirations

Masters Pharmaceutical customers will be able to take full advantage of these anticipated new generic releases.

\$56 billion losing patent expiration.



Projected Patent Expirations

\$56 billion worth of brand-name drugs are anticipated to lose patent protection in the next three years. Below is just a sampling of some of the more high-profile drugs to be released as generics.

| Brand Name | Generic Name | Indication | Patent Expiration | Retail Sales |
|---------------------|------------------------------------|------------------------------------|-------------------|--------------|
| Advair® Diskus | Fluticasone/Salmeterol | Asthma | October 2011 | \$3,572.4M |
| Arimidex® | Anastrozole | Breast Cancer | July 2010 | \$568.8M |
| Astelín® | Azelastine HCl | Seasonal Allergies | March 2010 | \$239.4M |
| Avandamet® | Rosiglitazone Maleate Metformin | Type 2 Diabetes | April 2012 | \$192.8M |
| Avandia® | Rosiglitazone Maleate | Type 2 Diabetes | April 2012 | \$513.7M |
| Avapro® | Irbesartan | Hypertension | April 2012 | \$405.6M |
| Caduet® | Amlodipine Atorvastatin | Hypertension, Cholesterol | December 2011 | \$388.4M |
| Effexor® XR | Venlafaxine HCl | Depression | July 2010 | \$2,657.7M |
| Femara® | Letrozole | Breast Cancer | February 2011 | \$361.0M |
| Flomax® | Tamsulosin | Benign Prostatic Hyperplasia (BPH) | March 2010 | \$1,237.0M |
| Kadian® | Morphine Sulfate | Pain Management | October 2010 | \$244.5M |
| Levaquin® | Levofloxacin | Bacterial Infections | June 2011 | \$1,461.1M |
| Lexapro® | Escitalopram Oxalate | Depression | March 2012 | \$2,412.0M |
| Lipitor® | Atorvastatin | Cholesterol | December 2011 | \$5,880.1M |
| Prevacid® | Lansoprazole | GERD | November 2009 | \$3,295.5M |
| Pulmicort® Respules | Budesonide | Asthma | December 2009 | \$651.0M |
| Valtrex® | Valacyclovir HCl | Viral Infections | January 2010 | \$1,684.2M |
| Xalatan® | Latanoprost | Glaucoma, Ocular Hypertension | March 2011 | \$456.3M |
| Yaz® | Ethinyl Estradiol/ Drospirenone | Birth Control | July 2011 | \$585.4M |
| Zyprexa® | Olanzapine | Schizophrenia | November 2011 | \$1,748.3M |



Source: U.S. retail sales figures are based on Drug Topics' Top 200 brand-name drugs by retail dollars in 2008, www.drugtopics.com. Earliest patent expiration date shown.

Masters Pharmaceutical makes no warranty, expressed or implied, about the accuracy of the data. These items and dates are only projected and are subject to change dependent.